Page last updated: 2024-09-04

canertinib and transforming growth factor alpha

canertinib has been researched along with transforming growth factor alpha in 2 studies

Compound Research Comparison

Studies (canertinib)	Trials (canertinib)	Recent Studies (post-2010) (canertinib)	Studies (transforming growth factor alpha)	Trials (transforming growth factor alpha)	Recent Studies (post-2010) (transforming growth factor alpha)
124	9	65	4,301	44	623

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arteaga, CL; Carpenter, G; Gazdar, AF; Muthuswamy, SK; Narasanna, A; Perez-Torres, M; Wang, SE; Wu, FY; Xiang, B; Yang, S	1
Brattain, MG; Foster, JM; Koterba, AP; Kreisberg, JI; Rajput, A; Willson, JK	1

Other Studies

2 other study(ies) available for canertinib and transforming growth factor alpha

Article	Year
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer cell, 2006, Volume: 10, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Nude; Models, Biological; Morpholines; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Transforming Growth Factor alpha; Trastuzumab; Xenograft Model Antitumor Assays	2006
A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer research, 2007, Jan-15, Volume: 67, Issue:2 Topics: Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Immunohistochemistry; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Morpholines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Signal Transduction; Transfection; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays	2007

Article

Year

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

Cancer cell, 2006, Volume: 10, Issue:1

Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Nude; Models, Biological; Morpholines; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Transforming Growth Factor alpha; Trastuzumab; Xenograft Model Antitumor Assays

2006

A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo.

Cancer research, 2007, Jan-15, Volume: 67, Issue:2

Topics: Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Immunohistochemistry; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Morpholines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Signal Transduction; Transfection; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays

2007